These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

38 related items for PubMed ID: 19062723

  • 1. [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors].
    Li Q, Feng FY, Chen Q, Jiao SC, Li F, Wang HQ, Huang WX, Ling CQ, Li MZ, Ren J, Zhang Y, Qin FZ, Zhou MZ, Zhu RZ.
    Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):534-7. PubMed ID: 19062723
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C, Hartmann JT, Schmittel A, Bokemeyer C, Schneller F, Keilholz U, Buchheidt D, Millan S, Izquierdo MA, Hofheinz RD.
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [Abstract] [Full Text] [Related]

  • 3. [Safety and effectiveness of large dose compound Sophora flavescens Ait injection in the treatment of advanced malignant tumors].
    Li DR, Lin HS.
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):291-4. PubMed ID: 21575502
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
    Eisen T, Thatcher N, Leyvraz S, Miller WH, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M.
    Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
    [Abstract] [Full Text] [Related]

  • 5. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D.
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [Abstract] [Full Text] [Related]

  • 6. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D, Graziano F, Isidori P, Santo A, Cetto G, Fedeli A, Rossi G, Cellerino R.
    Cancer; 1996 Jun 01; 77(11):2251-7. PubMed ID: 8635092
    [Abstract] [Full Text] [Related]

  • 7. [Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer].
    Yang L, Wang JW, Sun Y, Zhu YZ, Liu XQ, Li WL, Di LJ, Li PW, Wang YL, Song SP, Yao C, You LF.
    Zhonghua Zhong Liu Za Zhi; 2006 Feb 01; 28(2):138-41. PubMed ID: 16750022
    [Abstract] [Full Text] [Related]

  • 8. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.
    J Clin Oncol; 2009 Sep 10; 27(26):4274-80. PubMed ID: 19652055
    [Abstract] [Full Text] [Related]

  • 9. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
    Gatzemeier U, Heckmayer M, Neuhauss R, Schlüter I, von Pawel J, Wagner H, Dreps A.
    Semin Oncol; 1995 Dec 10; 22(6 Suppl 15):24-8. PubMed ID: 8643966
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC, Cheeseman S, Thatcher N, Anderson H, Carrington B, Hearn S, Ross G, Ranson M.
    Clin Cancer Res; 2000 Mar 10; 6(3):868-73. PubMed ID: 10741709
    [Abstract] [Full Text] [Related]

  • 11. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
    Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB.
    J Clin Oncol; 2004 Nov 15; 22(22):4456-62. PubMed ID: 15483017
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL.
    Cancer; 2002 Nov 15; 95(10):2044-50. PubMed ID: 12412156
    [Abstract] [Full Text] [Related]

  • 13. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
    Mantovani G, Macciò A, Mulas C, Massa E, Madeddu C, Mura L, Contu P, Versace R.
    Oncol Rep; 2002 Nov 15; 9(3):661-70. PubMed ID: 11956647
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R.
    Lung Cancer; 2009 Jun 15; 64(3):319-25. PubMed ID: 19095327
    [Abstract] [Full Text] [Related]

  • 15. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 Jun 15; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Yanagitani N, Tsuchiya S, Kaira K, Sunaga N, Tsuchiya Y, Sato K, Watanabe S, Nomura S, Sakai S, Saito R, Mori M.
    Am J Clin Oncol; 2007 Oct 15; 30(5):487-91. PubMed ID: 17921708
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J.
    J Clin Oncol; 2009 Aug 10; 27(23):3836-41. PubMed ID: 19597027
    [Abstract] [Full Text] [Related]

  • 18. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
    Martoni AA, Melotti B, Sperandi F, Giaquinta S, Piana E, Pavesi L, Da Prada G, Lelli G.
    Lung Cancer; 2008 Jun 10; 60(3):387-92. PubMed ID: 18160123
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
    Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H.
    J Clin Oncol; 2006 Feb 01; 24(4):688-94. PubMed ID: 16446342
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
    Takayama K, Kawasaki M, Ninomiya K, Motohiro A, Fujita M, Watanabe K, Kajiki A, Iwami F, Miyazaki N, Izumi M, Hara N, Nakanishi Y, Fukuoka Lung Cancer Study Group, Japan.
    Respirology; 2008 Jan 01; 13(1):103-7. PubMed ID: 18197918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 2.